Japan’s SBC Medical Group reported a 13% year-over-year increase in second-quarter revenue to $49 million, alongside a 32% rise in adjusted EBITDA to $20 million as of June 30, 2026. The group’s adjusted EBITDA margin expanded to 41%, supported by a 10% increase in trailing 12-month customer visits to 6.92 million and a 9% rise in average spend per visit.
The company’s clinic network grew to 287 locations, up 34 year-over-year, while same-clinic revenue rose 6% and year-to-date clinic revenue increased 11%. Aesthetic medicine accounted for 84% of transaction value, with non-aesthetic healthcare representing the remaining 16%, as the group diversifies beyond its core dermatology focus.
SBC outlined four core growth strategies during its Q3 Investor Summit presentation: accelerating a multi-brand aesthetic dermatology push, expanding non-aesthetic healthcare as a second engine, scaling globally via asset-light models in the U.S. and Southeast Asia, and enhancing competitiveness through AI-driven data reforms. The group’s 26-year operating history in Japan provides a foundation for these initiatives, with an AI chatbot already deployed and additional tools in development for call centers, customer support, and personalized services.
Global expansion includes a Phase 2 collaboration with U.S. partner OrangeTwist, where SBC will share operating expertise and explore longevity-focused services. In Southeast Asia, the group is testing an asset-light “Powered by SBC” model through a Thailand-based clinic, with plans to replicate the framework in Vietnam and other markets. OrangeTwist operates 24 locations across six states, generating over 40% of sales from recurring membership revenue.
Executive leadership highlighted progress in non-aesthetic healthcare, including the June 2026 establishment of a dedicated team led by Naoya Fujimoto, a former executive at a healthcare and IT talent platform company. Structural reforms completed in 2025 and the December 2025 acquisition of a minority stake in OrangeTwist were cited as key enablers of the group’s re-accelerated growth trajectory. SBC’s market capitalization stood at $437 million as of late August 2026, with a current ratio of 3.31 and undeployed cash of JPY 184 million.
Planned milestones include the 2027 opening of a longevity center and upcoming U.S. investor visits in September and October 2026 to further outline the group’s strategic roadmap.
